keliximab
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00718588)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD40 inhibitor
- T-cell surface antigen CD4INHIBITOR
CD4 inhibitor
- T-cell surface antigen CD4NEGATIVE MODULATOR
CD4 negative modulator
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108489 ↗
Also known as
- ce 9.1
- ce9.1
- idec-ce9.1
- keliximab
- keliximab
- mtrx1011a
- sb 210396
- sb-210396
- sb-210396
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00718588 | Phase 1 | Jul 1, 2008 | Genentech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1